Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$80.77
-0.7%
$91.83
$79.52
▼
$124.00
$20.43B1.281.09 million shs1.68 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$194.18
-2.6%
$206.87
$22.28
▼
$280.80
$78.57B1.1612.47 million shs9.64 million shs
Natera, Inc. stock logo
NTRA
Natera
$273.08
-5.8%
$376.63
$181.00
▼
$437.41
$39.60B1.551.48 million shs1.38 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$920.69
-0.3%
$826.97
$591.52
▼
$991.73
$95.25B0.1837,501 shs855,461 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-2.27%-4.32%-10.75%-30.20%-19.78%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%-13.84%-17.66%+37.40%+724.36%
Natera, Inc. stock logo
NTRA
Natera
+0.15%-10.22%-28.58%-12.68%+32.78%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-2.35%-2.93%+14.35%+10.71%+31.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$80.77
-0.7%
$91.83
$79.52
▼
$124.00
$20.43B1.281.09 million shs1.68 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$194.18
-2.6%
$206.87
$22.28
▼
$280.80
$78.57B1.1612.47 million shs9.64 million shs
Natera, Inc. stock logo
NTRA
Natera
$273.08
-5.8%
$376.63
$181.00
▼
$437.41
$39.60B1.551.48 million shs1.38 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$920.69
-0.3%
$826.97
$591.52
▼
$991.73
$95.25B0.1837,501 shs855,461 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-2.27%-4.32%-10.75%-30.20%-19.78%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%-13.84%-17.66%+37.40%+724.36%
Natera, Inc. stock logo
NTRA
Natera
+0.15%-10.22%-28.58%-12.68%+32.78%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-2.35%-2.93%+14.35%+10.71%+31.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.65
Moderate Buy$120.4449.49% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$120.25-38.34% Downside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$396.9343.91% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.74
Moderate Buy$904.41-2.78% Downside

Current Analyst Ratings Breakdown

Latest BNTX, REGN, MRNA, and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Natera, Inc. stock logo
NTRA
Natera
Set Price TargetBuy$490.00
11/19/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Boost Price TargetNeutral$92.00 ➝ $93.00
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderweight$77.00 ➝ $102.00
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$95.00 ➝ $200.00
11/17/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Boost Price TargetOverweight$917.00 ➝ $1,075.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingOverweight$230.00 ➝ $305.00
11/9/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$130.00 ➝ $110.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$137.00 ➝ $195.00
11/9/2026
Natera, Inc. stock logo
NTRA
Natera
Lower Price TargetOutperform$458.00 ➝ $403.00
11/6/2026
Natera, Inc. stock logo
NTRA
Natera
Reiterated RatingOverweight$363.50
11/6/2026
Natera, Inc. stock logo
NTRA
Natera
Lower Price TargetOverweight$460.00 ➝ $405.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B6.28$1.29 per share62.36$80.61 per share1.00
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B40.59N/AN/A$16.90 per share11.54
Natera, Inc. stock logo
NTRA
Natera
$2.31B17.34N/AN/A$12.89 per share21.40
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B6.71$41.31 per share22.52$323.82 per share2.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$6.85N/AN/AN/A-61.39%-4.51%-3.96%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.10N/AN/AN/A-110.46%-25.79%-15.85%N/A
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.14N/AN/AN/A-5.66%-8.61%-5.93%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$45.2920.4814.821.2528.51%16.01%12.22%1/28/2027 (Estimated)

Latest BNTX, REGN, MRNA, and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10$0.38+$1.48$0.38$890.25 million$1.31 billion
11/5/2026Q3 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.2810-$0.42-$0.1390-$0.42$707.54 million$793.98 million
10/30/2026Q3 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$16.51$20.07+$3.56$18.45$4.58 billion$5.12 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.41%N/A8.30%N/A

Latest BNTX, REGN, MRNA, and NTRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.41%11/20/202611/20/202612/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.55
8.52
Moderna, Inc. stock logo
MRNA
Moderna
0.52
3.62
3.47
Natera, Inc. stock logo
NTRA
Natera
N/A
2.81
2.66
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.35
2.89

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700404.62 million360.92 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140145.01 million137.68 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410103.45 million96.24 millionOptionable

Recent News About These Companies

Here's Why Regeneron (REGN) is a Strong Momentum Stock
REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
FDA approves Regeneron's Livsayis for myasthenia gravis
FDA nod for Regeneron’s Livsayis in gMG
Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
Livsayis FDA Approval Hands Regeneron a New Neurology Franchise
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$80.77 -0.61 (-0.75%)
Closing price 03:58 PM Eastern
Extended Trading
$81.00 +0.23 (+0.28%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$194.18 -5.15 (-2.58%)
Closing price 03:58 PM Eastern
Extended Trading
$197.50 +3.32 (+1.71%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera stock logo

Natera NASDAQ:NTRA

$273.08 -16.84 (-5.81%)
Closing price 03:59 PM Eastern
Extended Trading
$274.40 +1.31 (+0.48%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$920.69 -2.65 (-0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$920.52 -0.17 (-0.02%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.